1. Home
  2. JYNT vs VIGL Comparison

JYNT vs VIGL Comparison

Compare JYNT & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JYNT
  • VIGL
  • Stock Information
  • Founded
  • JYNT 2010
  • VIGL 2020
  • Country
  • JYNT United States
  • VIGL United States
  • Employees
  • JYNT N/A
  • VIGL N/A
  • Industry
  • JYNT Multi-Sector Companies
  • VIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • JYNT Miscellaneous
  • VIGL Health Care
  • Exchange
  • JYNT Nasdaq
  • VIGL Nasdaq
  • Market Cap
  • JYNT 163.0M
  • VIGL 141.1M
  • IPO Year
  • JYNT 2014
  • VIGL 2022
  • Fundamental
  • Price
  • JYNT $10.87
  • VIGL $3.42
  • Analyst Decision
  • JYNT Strong Buy
  • VIGL Buy
  • Analyst Count
  • JYNT 2
  • VIGL 5
  • Target Price
  • JYNT $18.00
  • VIGL $16.60
  • AVG Volume (30 Days)
  • JYNT 33.1K
  • VIGL 121.7K
  • Earning Date
  • JYNT 08-08-2024
  • VIGL 08-13-2024
  • Dividend Yield
  • JYNT N/A
  • VIGL N/A
  • EPS Growth
  • JYNT N/A
  • VIGL N/A
  • EPS
  • JYNT N/A
  • VIGL N/A
  • Revenue
  • JYNT $120,071,078.00
  • VIGL N/A
  • Revenue This Year
  • JYNT $1.50
  • VIGL N/A
  • Revenue Next Year
  • JYNT N/A
  • VIGL N/A
  • P/E Ratio
  • JYNT N/A
  • VIGL N/A
  • Revenue Growth
  • JYNT 7.46
  • VIGL N/A
  • 52 Week Low
  • JYNT $7.31
  • VIGL $2.47
  • 52 Week High
  • JYNT $17.82
  • VIGL $9.24
  • Technical
  • Relative Strength Index (RSI)
  • JYNT 34.42
  • VIGL 46.18
  • Support Level
  • JYNT $10.89
  • VIGL $3.20
  • Resistance Level
  • JYNT $11.46
  • VIGL $3.78
  • Average True Range (ATR)
  • JYNT 0.31
  • VIGL 0.30
  • MACD
  • JYNT 0.05
  • VIGL 0.03
  • Stochastic Oscillator
  • JYNT 12.16
  • VIGL 36.67

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

Share on Social Networks: